Priority Lists
Protocol Posting of
Activations
Phase II Trial of CG8123, an Autologous Cancer Vaccine (GVAX), in Patients with Selected Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC).
Study Coordinator(s) | Angela M. Davies, M.D., Raja Mudad, M.D., FACP, Peter F. Roberts, M.D., Derick H.M. Lau, M.D.,Ph.D., Deborah S. Ward, NP |
Participants | Limited: Institutions Listed on the Title Page |
Activation
Standard Dose Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) and Rituximab, or Rituximab and G3139 Phosphorothioate Oligonucleotide (BCL-2 Antisense - NSC-683428) Therapy for Young Patients (< Age 60) with Advanced Stage Diffuse Large B-cell NHL of Low and Low-Intermediate IPI Risk
Study Coordinator(s) | Steven Bernstein, M.D., Richard I. Fisher, M.D., Thomas M. Grogan, M.D. |
Participants | Members, NCORP, Affiliates, Medical Oncologists, Pathologists |
Closures
Permanent closure effective 3/31/04
A Three-Arm Randomized Trial To Compare Adjuvant Adriamycin, Taxotere, and Cyclophosphamide (ATC) in Breast Cancer Patients With Positive Axillary Lymph Nodes
Study Coordinator(s) | Robert B. Livingston, M.D. |
Participants | CTSU |
Closure Date | 2004-03-31 |
Permanently closed: 2/18/04
A Randomized, Placebo-controlled, Double-blind Trial Evaluating the Effect of Exemestane in Clinical cT1-3NO-1MO Postmenopausal Breast Cancer Patients Completing at Least Five Years of Tamoxifen Therapy
Study Coordinator(s) | Laura F. Hutchins, M.D. |
Participants | CTSU |
Closure Date | 2004-02-18 |
Permanent closure effective 3/31/04
A Clinical Trial Comparing Adjuvant Clodronate Therapy vs Placebo in Early Stage Breast Cancer Patients Receiving Systemic Chemotherapy and/or Tamoxifen or No Therapy
Action Codes | IP, ER |
Study Coordinator(s) | Julie R. Gralow, M.D. |
Participants | CTSU |
Closure Date | 2004-03-31 |
Amendments, Revisions, Memoranda
Revision #4
Phase III Randomized Trial of Fludarabine and Cyclophosphamide versus Fludarabine for Previously Untreated Chronic Lymphocytic Leukemia.
Study Coordinator(s) | Mohamad A. Hussein, M.D. |
Participants | Members, NCORP, Medical Oncologists, Pathologists |
Memorandum
A Phase III Randomized Double Blind Study of Letrozole Versus Placebo in Women With Primary Breast Cancer Completing Five or More Years of Adjuvant Tamoxifen
Study Coordinator(s) | Silvana Martino, D.O. |
Memorandum
Selenium and Vitamin E Cancer Prevention Trial (SELECT)
Study Coordinator(s) | Eric A. Klein, M.D., Ian M. Thompson Jr., M.D., Wael A. Sakr, M.D. |
Participants | Institutions listed in protocol Appendix 19.5 |
Revision #9
Phase II Evaluation Of Neoadjuvant Chemotherapy, Interval Debulking Followed By Intraperitoneal Chemotherapy In Women With Stage III And IV Epithelial Ovarian Cancer, Fallopian Tube Cancer Or Primary Peritoneal Cancer
Study Coordinator(s) | Amy D. Tiersten, M.D., Harriet O. Smith, M.D., Sharon Wilczynski, M.D.,Ph.D. |
Participants | Members, NCORP, Surgeons |
Revision #11
A Phase III Trial of Cisplatin/Etoposide/Radiotherapy with Consolidation Docetacel followed by Maintenance Therapy with ZD1839 (NSC-715055) or Placebo in Patients with Inoperable Locally Advanced Stage III Non-Small Cell Lung Cancer
Study Coordinator(s) | Karen Kelly, M.D., Laurie E. Gaspar, M.D., Wilbur A. Franklin, M.D., David R. Gandara, M.D., Paul H. Gumerlock, Ph.D. |
Participants | Members, NCORP, Medical Oncologists, Radiation Oncologists, NCCTG, NCIC-CTG, CTSU, EPP |
Revision #1
Phase II Trial of Irinotecan (Camptosar) for Patients with Platinum and Taxane Refractory Ovarian, Peritoneal or Fallopian Tube Cancer
Study Coordinator(s) | Amy D. Tiersten, M.D., William R. Robinson, M.D. |
Participants | Members, NCORP, Medical Oncologists, Surgeons, Pathologists |
Revision #4
A Phase II Study of Gemtuzumab Ozogamicin (Mylotarg™) and Standard Dose Ara-C for Patients With Relapsed Acute Myeloid Leukemia (AML)
Study Coordinator(s) | John E. Godwin, M.D., Margaret R. O'Donnell, M.D., David R. Head, M.D., Marilyn L. Slovak, Ph.D., Cheryl L. Willman, M.D. |
Participants | Members, NCORP, Medical Oncologists, Pathologists |
Amendment #1
Phase II Evaluation of Carboplatin, Paclitaxel and Gemcitabine Followed by Concurrent Cisplatin and Radiation Therapy in Patients with Locally Advanced or Recurrent Urothelial Malignancy
Study Coordinator(s) | Ulka N. Vaishampayan, M.D., Maha H.A. Hussain, M.D., Jeffrey D. Forman, M.D., Paul H. Gumerlock, Ph.D. |
Participants | Members, NCORP, UCOP, Medical Oncologists, Radiation Oncologists, Surgeons, Pathologists |
Revision #1
Phase II Evaluation of Carboplatin, Paclitaxel and Gemcitabine Followed by Concurrent Cisplatin and Radiation Therapy in Patients with Locally Advanced or Recurrent Urothelial Malignancy
Study Coordinator(s) | Ulka N. Vaishampayan, M.D., Maha H.A. Hussain, M.D., Jeffrey D. Forman, M.D., Paul H. Gumerlock, Ph.D. |
Participants | Members, NCORP, UCOP, Medical Oncologists, Radiation Oncologists, Surgeons, Pathologists |
Revision #1
A Phase II Trial of Gemcitabine (NSC-613327) and Capecitabine (NSC-712807) in Patients with Unresectable or Metastatic Gallbladder or Cholangiocarcinoma
Study Coordinator(s) | Heinz- Josef Lenz, M.D. |
Participants | Members, NCORP, Medical Oncologists |
Memorandum
A Phase II Trial of Thalidomide/Dexamethasone Induction Followed by Tandem Melphalan Transplant and Prednisone/Thalidomide Maintenance in Newly Diagnosed Multiple Myeloma Patients, (A BMT Study)
Action Codes | ER |
Study Coordinator(s) | Mohamad A. Hussein, M.D., John D. Shaughnessy, Jr., Ph.D., James A. Waldron, M.D.,Ph.D., Jeffrey A. Zonder, M.D. |
Participants | Members, NCORP, Medical Oncologists, Pathologists, Limited Institutions: BMT Members |
Memorandum
A Phase III Randomized Open-Label Study Comparing Gemcitabine Plus Cetuximab (IMC-C225) Versus Gemcitabine as First-Line Therapy of Patients with Advanced Pancreas Cancer
Action Codes | ER |
Study Coordinator(s) | Philip A. Philip, M.D.,Ph.D., Cecilia M. Fenoglio-Preiser, M.D., Ralph Wong, M.D., Nancy Vaught, R.N.,O.C.N |
Participants | Members, NCORP, Medical Oncologists, CTSU |
Revision #1
A Phase III Randomized Open-Label Study Comparing Gemcitabine Plus Cetuximab (IMC-C225) Versus Gemcitabine as First-Line Therapy of Patients with Advanced Pancreas Cancer
Action Codes | ER |
Study Coordinator(s) | Philip A. Philip, M.D.,Ph.D., Cecilia M. Fenoglio-Preiser, M.D., Ralph Wong, M.D., Nancy Vaught, R.N.,O.C.N |
Participants | Members, NCORP, Medical Oncologists, CTSU |
Amendment #1
A Phase I Pharmacokinetic Study of Epothilone B Analogue BMS-247550 (NSC-710428D) in Patients with Advanced Malignancies and Varying Levels of Liver Dysfunction.
Study Coordinator(s) | Angela M. Davies, M.D., Timothy W. Synold, Pharm. D., Chris Takimoto, M.D. |
Participants | Limited: Institutions Listed on the Title Page |
Other New Items
- IP - Pts Must Be Informed
- AC - Consent Must Be Amended
- CBR - No Registration Allowed until IRB Review
- RC - Formal Re-consent Required
- FBR - Full Board Review Required
- ER - Expedited Review Acceptable
- NR - No IRB Review Required